Trial · NCT03482635
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients With Clinical Remission at Week 12 | Placebo | 0.00 | 95% Confidence Interval 0.000 to 0.143 | Proportion of Participants | |
| Proportion of Patients With Clinical Remission at Week 12 | 300 mg Spesolimab (BI 655130) SD | 0.042 | 95% Confidence Interval 0.007 to 0.202 | Proportion of Participants | |
| Proportion of Patients With Clinical Remission at Week 12 | 450 mg Spesolimab (BI 655130) q4w | 0.087 | 95% Confidence Interval 0.024 to 0.268 | Proportion of Participants | |
| Proportion of Patients With Clinical Remission at Week 12 | 1200 mg Spesolimab (BI 655130) q4w | 0.071 | 95% Confidence Interval 0.020 to 0.226 | Proportion of Participants | |
| Proportion of Patients With Clinical Response at Week 12 | Placebo | 0.217 | 95% Confidence Interval 0.097 to 0.419 | Proportion of participants | |
| Proportion of Patients With Clinical Response at Week 12 | 300 mg Spesolimab (BI 655130) SD | 0.167 | 95% Confidence Interval 0.067 to 0.359 | Proportion of participants | |
| Proportion of Patients With Clinical Response at Week 12 | 450 mg Spesolimab (BI 655130) q4w | 0.261 | 95% Confidence Interval 0.125 to 0.465 | Proportion of participants | |
| Proportion of Patients With Clinical Response at Week 12 | 1200 mg Spesolimab (BI 655130) q4w | 0.250 | 95% Confidence Interval 0.127 to 0.434 | Proportion of participants | |
| Proportion of Patients With Endoscopic Improvement at Week 12 | Placebo | 0.000 | 95% Confidence Interval 0.000 to 0.143 | Proportion of participants | |
| Proportion of Patients With Endoscopic Improvement at Week 12 | 300 mg Spesolimab (BI 655130) SD | 0.083 | 95% Confidence Interval 0.023 to 0.258 | Proportion of participants | |
| Proportion of Patients With Endoscopic Improvement at Week 12 | 450 mg Spesolimab (BI 655130) q4w | 0.087 | 95% Confidence Interval 0.024 to 0.268 | Proportion of participants | |
| Proportion of Patients With Endoscopic Improvement at Week 12 | 1200 mg Spesolimab (BI 655130) q4w | 0.071 | 95% Confidence Interval 0.020 to 0.226 | Proportion of participants | |
| Proportion of Patients With Combined Endoscopic Improvement and Histologic Remission at Week 12 | Placebo | 0.00 | 95% Confidence Interval 0.000 to 0.143 | Proportion of participants | |
| Proportion of Patients With Combined Endoscopic Improvement and Histologic Remission at Week 12 | 300 mg Spesolimab (BI 655130) SD | 0.083 | 95% Confidence Interval 0.023 to 0.258 | Proportion of participants | |
| Proportion of Patients With Combined Endoscopic Improvement and Histologic Remission at Week 12 | 450 mg Spesolimab (BI 655130) q4w | 0.043 | 95% Confidence Interval 0.008 to 0.210 | Proportion of participants | |
| Proportion of Patients With Combined Endoscopic Improvement and Histologic Remission at Week 12 | 1200 mg Spesolimab (BI 655130) q4w | 0.036 | 95% Confidence Interval 0.006 to 0.177 | Proportion of participants | |
| Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline at Week 12 | Placebo | 19.8 | 95% Confidence Interval 4.7 to 35.0 | Score on a scale | |
| Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline at Week 12 | 300 mg Spesolimab (BI 655130) SD | 19.5 | 95% Confidence Interval 4.6 to 34.5 | Score on a scale | |
| Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline at Week 12 | 450 mg Spesolimab (BI 655130) q4w | 21.2 | 95% Confidence Interval 6.6 to 35.9 | Score on a scale | |
| Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline at Week 12 | 1200 mg Spesolimab (BI 655130) q4w | 20.8 | 95% Confidence Interval 6.3 to 35.4 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03482635/results